OncoMax successfully presented at the Annual Congress of the American Association for Cancer Research (AACR)

OncoMax, financed by Maxwell Biotech Venture Fund, set up with the participation of RVC OJSC and RVC Seed Fund, presented the results of its studies in the sphere of oncology at the Annual Congress of the American Association for Cancer Research (AACR), held in Chicago on April 1–4, 2012.

Considering the results of the studies of the efficacy of OncoMax’s OM-RCA-01 drug, a monoclonal antibody, intended for the therapy and diagnostics of the renal cell carcinoma, chief scientific advisor of the company doctor I.V. Tsimafeyeu in his poster report released the latest achievements in the inhibition of the growth of the cancer tumour in the kidney tissues by blocking fibroblast growth factor receptor (FGFR1).

The Annual Congress of AACR is one of the most important events for fundamental researchers in oncology, that attracts several thousands of representatives of research institutes, biotechnological companies and leading pharmaceutical producers representatives from all over the world. At the poster session, OncoMax project and its success in the development of OM-RCA-01 drug sparked the interest of the world’s largest pharmaceutical companies — Merck, Bayer, Imclone, Eli Lilly, Pfizer and others.

The next international scientific congress, where the representatives of OncoMax are going to report the results of the conducted studies of OM-RCA-01, will be the Annual Conference of the American Society of Clinical Oncology (ASCO), that will be held in Chicago in June 1 – 5, 2012.

 

Анна Зеленкова,
PR директор, ООО «Максвелл Биотех Групп»;
Тел: +7 (495) 411-6992
E-mail: zelenkova@maxwellbiotech.ru